The most effective way to get patients to stick with their medication regimens all the way through their therapy, it turns out, is to give the job to community pharmacists. That means giving them time and adequate compensation to do what they do best: counsel and monitor patients, one-on-one.
Adherence interventions targeted to nonadherent patients proved more effective in improving medication adherence when compared with broad interventions that cast a wide net to encompass all medication takers, according to new research sponsored by CVS Caremark.
Following the Senate’s defeat of a proposal that would have permitted “personal importation” of prescription drug medications, the National Association of Chain Drug Stores lauded the Senate’s decision to support patient safety.
The $317 billion problem of medication nonadherence has many sources that often combine and overlap in complex ways. But fears of whether a drug is safe and will work are among of the most frequently cited reasons why patients don't take their drugs as prescribed, or don't take them at all.
Food and Drug Administration drug warnings can have an immediate negative impact on medication adherence among patients, even if the warnings are not safety related, according to new research sponsored by CVS Caremark.
Retail pharmacy veteran Frank Scorpiniti officially assumed the role of CEO of Rexall Pharma Plus in February. Now that he’s settled in North of the Border, Scorpiniti talked with Drug Store News about his new role and his insights on the Canadian retail pharmacy market.
More than 80% of health plans would require a drug manufacturer to demonstrate a clear clinical benefit compared with current branded and generic treatments in order for its drug to be placed in the plan's formulary, according to a new survey.
The Centers for Medicare and Medicaid Services earlier this month released a memo to all Part D sponsors, warning them that the agency has "observed an increase in beneficiary complaints related to the transfer of prescriptions from retail pharmacies to either mail-order or specialty pharmacy without their explicit consent."
CVS Caremark has aggressively set its sights on enhancing medication adherence, and the initiatives are paying off as the company estimates that its PBM clients saved nearly $2.4 billion in 2011 because of improved medication adherence for chronic conditions, according to findings of its annual Insights Report.
Big trends can sometimes take centuries or even millennia to develop. Think about how long it took between the dawn of anatomically modern humans and the adoption of agriculture. Health care is no different, having come a long way since the days of bloodletting and the assorted quackeries that were once considered acceptable medical practices.
The number of prescriptions being sent electronically jumped by 75% between 2010 and 2011, while almost all of the retail pharmacies in the country are connected for e-prescribing, according to a new report by the country's largest e-prescribing network.
The National Association of Chain Drug Stores has emphasized the commitment of NACDS and the chain pharmacy industry to partner with policy-makers and others to improve quality and lower costs in the healthcare delivery system in a statement sent to the U.S. Senate Health, Education, Labor and Pensions Committee.
Medication nonadherence costs the U.S. healthcare system about $290 billion per year, according to New England Healthcare Institute. That big and scary number — the kind whose sheer enormity can make one’s eyes glaze over — is now even bigger.
Legislation proposed in the House of Representatives would speed up Food and Drug Administration approval of knock-off versions of vaccines and other biologics while requiring the agency to conduct more inspections of drug factories overseas, according to published reports.
Walgreens on Tuesday infused greater value into its Prescription Savings Club program, which now offers discounts on more than 8,000 brand-name and generic prescriptions, thanks to the inclusion of more than 700 "value-priced" generics, which retail as low as $12 for a 90-day supply.